Trogenix Moves Toward Clinic After Nature Study Shows Complete Tumor Clearance in GBM Model

New updates have been reported about Trogenix.

Trogenix Ltd is accelerating its shift into a clinical-stage oncology company after publishing pre-clinical data in Nature showing complete tumor eradication and durable protection in an aggressive glioblastoma (GBM) model that closely reflects human disease. The study validates the company’s Synthetic Super-Enhancer (SSE) gene-control platform, delivered via adeno-associated virus vectors, which selectively targets SOX2- and SOX9-driven transcriptional networks active in GBM stem cells while sparing normal brain tissue.

The data underpin Trogenix’s planned Phase I/II ADePT trial in GBM, with first patient dosing expected in Q2 2026, positioning the company to test a potentially curative, single-dose gene therapy in humans. Trogenix’s dual-payload construct combines HSV-TK for direct tumor cell killing with IL-12 to stimulate the immune system, effectively functioning as an in situ vaccine that generates long-term immunologic memory against cancer recurrence.

In pre-clinical models, this approach delivered complete tumor elimination and long-lasting protection from relapse without detectable off-target toxicity, a result described by Chief Scientific Officer and co-founder Professor Steve Pollard as achieving what was previously considered impossible in GBM. Crucially, SSE activity was confirmed in fresh patient GBM samples with no expression in healthy brain tissue, reducing the risk of systemic toxicity and supporting regulatory progression into first-in-human studies.

Backed by a £70 million ($95 million) Series A financing completed in October 2025 and prior seed capital from specialist life sciences investors and strategic partners, Trogenix now has funding to push its GBM program and broader solid tumor pipeline rapidly into the clinic. The company, spun out of the University of Edinburgh in 2024 and incubated by 4BIO Capital, is also advancing pre-clinical programs in hepatocellular carcinoma and colorectal cancer liver metastases, aiming to apply its Odysseus platform across multiple aggressive solid tumors.

Cancer Research Horizons, a key supporter alongside Cancer Research UK and the Biotechnology and Biological Sciences Research Council, views the Nature publication as a critical milestone that de-risks Trogenix’s entry into clinical development. With a mechanistically differentiated platform, validated selective targeting, and substantial capital in place, Trogenix is positioned to test whether its precision viral immunotherapy can translate pre-clinical curative-like responses in GBM into meaningful patient and value inflection points over the next clinical cycle.